Hypomania Associated With Mirtazapine Augmentation of Sertraline
J Clin Psychiatry 1998;59(6):320-320 [letter]
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Sir: Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA). Its novel mechanism of action involves α2-adrenergic autoreceptor and heteroreceptor blockade, enhancing serotonin (5-HT) and norepinephrine release; and 5-HT2, 5-HT3, and histamine H1 antagonism. Because mirtazapine blocks 5-HT2 and 5-HT3 receptors, 5-HT1-mediated transmission is enhanced.